Biofluidic chip technology for studying sickle cell disease
Sickle Cell Disease (SCD) Biochip': Towards a Simple and Reliable Way to Monitor Sickle Cell Disease
University Hospitals Cleveland Medical Center · NCT02824471
This study is testing a new technology that looks closely at the cells of people with sickle cell disease to better understand how their cells behave and interact.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 12 Years and up |
| Sex | All |
| Sponsor | University Hospitals Cleveland Medical Center (other) |
| Locations | 1 site (Cleveland, Ohio) |
| Trial ID | NCT02824471 on ClinicalTrials.gov |
What this trial studies
This observational study aims to utilize novel biofluidic chip technology to investigate the surface characteristics of cells in patients with sickle cell disease (SCD). By capturing cell populations without extensive processing, the SCD biochip allows for a systematic examination of cellular membrane properties and activation status. The study seeks to enhance understanding of the interactions and abnormalities associated with SCD across various clinical phenotypes. This innovative approach could provide insights that traditional methods may overlook.
Who should consider this trial
Good fit: Ideal candidates include males and females aged 12 years and older with a documented diagnosis of sickle cell disease.
Not a fit: Patients with conditions that may compromise their safety or the quality of the data will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of sickle cell disease.
How similar studies have performed: While similar biofluidic technologies have been explored, this specific application in sickle cell disease is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria * Male or female ≥12 years of age at the time of consent (enrollment). * Documentation Sickle Cell Disease, including HbSS or compound heterozygus HbSC- or HbSβ- thalassemia diagnosis as evidenced by one or more clinical features. * Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study. Exclusion Criteria * Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Where this trial is running
Cleveland, Ohio
- University Hospitals Case Medical Center — Cleveland, Ohio, United States (RECRUITING)
Study contacts
- Principal investigator: Amma Owusu-Ansah, MD — University Hospitals Cleveland Medical Center
- Study coordinator: Umut Gurkan, PhD
- Email: umut@case.edu
- Phone: (216) 368-6447
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Sickle Cell Disease, Biofluidic Chip Technology